Prognostic Value of DTA Mutations in Patients with Newly Diagnosed Acute Mveloid Leukemia
10.19746/j.cnki.issn1009-2137.2024.04.003
- VernacularTitle:DTA突变在初诊急性髓系白血病患者中的预后价值
- Author:
Hui-Juan CHEN
1
;
Yang CAO
;
Ying-Jie MIAO
;
Yi-Fang ZHOU
;
Yue LIU
;
Wei-Ying GU
Author Information
1. 苏州大学附属第三医院,常州市第一人民医院血液科,江苏常州 213003
- Keywords:
DTA mutation;
clonal hematopoiesis;
acute myeloid leukemia;
prognosis
- From:
Journal of Experimental Hematology
2024;32(4):993-998
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the prognostic significance of DTA(DNMT3A,TET2,ASXL1)gene mutations in patients with non-M3 acute myeloid leukemia(AML).Methods:The clinical data of 180 newly diagnosed AML patients hospitalized in the First People's Hospital of Changzhou from January 2018 to April 2022 were retrospectively analyzed.Next-generation sequencing technology was used to detect 150 gene mutations in the patients,and log-rank tests and Cox regression models were used to analyze the prognostic factors.Results:DTA gene mutations were detected in 83(46.1％)of 180 AML patients.Compared to patients without DTA mutations,patients with DTA mutations were significantly older(P＜0.001).The median overall survival(OS)time and disease-free survival(DFS)time in the DTA mutation group were significantly shorter than those in the group without DTA mutation(both P＜0.05).Multivariate analysis showed that age ≥ 60 years(P＜0.001),with DTA mutation(P=0.018),and intermediate-risk(relative to favorable-risk)(P=0.005)were independent risk factors for OS in AML patients.Conclusion:AML patients with DTA mutations are relatively older,with shorter median OS time and DFS time,and poor prognosis.
